Oncotelic Therapeutics (OTLC) AI Stock Analysis

• Market Cap: $37.71M
• Dividend Yield: N/A
• Average Volume (3M): 410.07K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.42
• Revenue Growth: N/A
• EPS Growth: 65.22%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 442,596,600
• 10 Day Avg. Volume: 544,661
• 30 Day Avg. Volume: 410,075
• PEG Ratio: <0.01
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.12
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -57.75
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $0.08 ▲(5.00% Upside)

The score is primarily held down by weak financial performance (minimal revenue, ongoing losses, and negative cash flow) and limited valuation support due to a negative P/E and no dividend. Technical signals are also soft (negative MACD and sub-50 RSI). Offsetting factors are modestly positive corporate developments around financing initiatives, potential uplisting efforts, and a product/platform announcement.

Positive Factors

Proprietary Data Platform

Launching PDAOAI creates a durable, non-clinical asset that can deepen scientific engagement, enable translational research partnerships, and support recurring services or collaborations. Over months this can differentiate the company through data capabilities and broaden pathways to monetization beyond drug trials.

Access to Private Capital with Registration Rights

Structured private financings with registration rights provide tangible runway and investor protections that can improve liquidity and enable continued R&D investment. For a pre-revenue biotech, secured access to capital materially lowers the near-term risk of program interruption while management advances strategic milestones.

Improving Cash Burn Trend

A materially smaller TTM loss versus prior-year levels indicates better spending discipline and incremental progress toward cash efficiency. Sustained lower burn increases the odds management can reach technical or regulatory inflection points before requiring substantially dilutive financings.

Negative Factors

Minimal Revenue Base

Lack of a recurring revenue engine forces ongoing reliance on external funding to support operations and development. Over a multi-month horizon this structural absence of revenue keeps the company exposed to financing cycles and heightens dilution and execution risk if clinical or platform milestones slip.

High Leverage for Pre-Revenue Biotech

Meaningful debt relative to equity constrains financial flexibility for a company without stable cash inflows. Interest and maturity obligations can crowd R&D spending, elevate refinancing risk, and reduce strategic optionality if capital markets tighten or milestone timing shifts over the coming months.

Reliance on Convertible Notes and Complex Securities

Frequent use of convertible notes, extended warrants, and cross-company conversion options increases potential dilution and creates contingent obligations. This capital structure complexity can alter investor incentives and magnify share-count risk if conversions occur, pressuring existing holders over a multi-month financing cycle.

Oncotelic Therapeutics Business Overview & Revenue Model

Company Description

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

How the Company Makes Money

Oncotelic Therapeutics primarily generates revenue through the development and commercialization of its therapeutic candidates. The company's revenue model includes securing funding through partnerships, grants, and licensing agreements with other pharmaceutical companies and research institutions. Additionally, Oncotelic may earn revenue through milestone payments and royalties from successful collaborations and the eventual commercialization of its drug candidates. The company's earnings are significantly influenced by its ability to advance its drugs through clinical trials and achieve regulatory approvals, which can lead to increased licensing opportunities and partnerships.

Oncotelic Therapeutics Financial Statement Overview

Summary

Overall financial profile is weak: minimal-to-no revenue, ongoing net losses, and consistently negative operating/free cash flow. Improving loss and burn trends are a positive, but rising leverage (debt ~1.9x equity) increases funding and solvency risk for a low-revenue biotech.

Income Statement

The company has minimal-to-no revenue in most periods (including 2024 annual and 2025-09-30 TTM (Trailing-Twelve-Months)), with persistent operating losses and negative EBITDA/EBIT across the dataset—typical of an early-stage biotech but still a clear earnings weakness. Net losses remain significant (TTM net loss of about $1.7M), and profitability is not yet evident. A notable positive is that the TTM loss is much smaller than the 2023 annual loss, suggesting spending discipline or a reduced cost base, but the lack of a consistent revenue engine keeps the income statement profile very weak.

Balance Sheet

The balance sheet shows meaningful leverage for a pre-revenue/low-revenue biotech: total debt rises to ~$17.4M in the latest TTM period versus ~$9.0M in 2021, and debt is ~1.9x equity in TTM, which increases financial risk. Equity is still positive (~$9.1M TTM) and total assets are relatively stable (~$28.2M TTM), providing some balance-sheet support. However, returns on equity are negative in the most recent periods, reflecting that losses are eroding shareholder value, and the higher debt load reduces flexibility.

Cash Flow

Cash generation remains a key concern: operating cash flow and free cash flow are negative in every period shown, including TTM operating cash flow of about -$0.7M. The burn rate appears to be improving versus earlier years (e.g., 2021’s much larger cash outflow), and TTM free cash flow is less negative than 2023 and 2022, which is constructive. Still, the business is not self-funding, and negative operating cash flow implies continued reliance on financing (debt/equity raises) to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	70.00K	0.00	0.00	1.74M
Gross Profit	0.00	0.00	70.00K	-12.84K	-61.51K	1.74M
EBITDA	-863.01K	-3.55M	-7.16M	-5.60M	-9.06M	-7.61M
Net Income	-1.67M	-4.52B	-7.90M	17.82M	-11.39M	-11.50M
Balance Sheet
Total Assets	28.16M	26.68M	30.01M	36.12M	23.61M	23.66M
Cash, Cash Equivalents and Short-Term Investments	409.00K	86.13K	170.41K	241.45K	568.77K	474.02K
Total Debt	17.41M	13.09M	12.57M	11.26M	8.99M	5.43M
Total Liabilities	20.08M	19.20M	18.40M	16.92M	15.45M	11.18M
Stockholders Equity	9.05M	8.25M	12.13M	19.41M	7.96M	11.77M
Cash Flow
Free Cash Flow	-704.01K	-740.27K	-1.32M	-1.45M	-4.43M	-2.81M
Operating Cash Flow	-704.01K	-740.27K	-1.32M	-1.45M	-4.43M	-2.81M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	964.00K	656.00K	1.25M	1.13M	4.53M	3.22M

Oncotelic Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and above the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.99 is Neutral, neither overbought nor oversold. The STOCH value of 39.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.

Oncotelic Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$58.80M	-6.50	-13.15%	―	―	45.97%
LTRN	52 Neutral	$37.92M	-1.93	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CALC	51 Neutral	$76.80M	-3.32	-526.36%	―	―	-2.46%
OTLC	47 Neutral	$37.71M	-20.73	-38.38%	―	―	65.22%
ELUT	46 Neutral	$29.49M	-0.75	―	―	-14.92%	72.81%
MAIA	44 Neutral	$61.47M	-2.23	-2691.06%	―	―	44.50%

Oncotelic Therapeutics Corporate Events

Oncotelic Therapeutics Lowers Milestone Thresholds to Aid Uplisting

On January 6, 2026, Oncotelic Therapeutics, Inc. announced amendments to an independent contractor agreement with Jefferson Capital Ventures, LLC, originally dated August 6, 2025, and to a restricted stock award agreement dated November 17, 2025, with its CEO, Dr. Vuong Trieu, both tied to the achievement of corporate milestones. The company lowered the market capitalization threshold for the first milestone from $100 million to $45 million, affecting Jefferson’s restricted common stock awards and Dr. Trieu’s restricted preferred stock awards, while leaving all other milestone terms unchanged; this move is intended to support execution of Oncotelic’s ongoing initiatives, including using its equity line with Mast Hills, advancing future financing arrangements, and working toward uplisting its stock to a nationally recognized exchange, thereby potentially improving its capital access and strategic positioning.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Oncotelic revises incentive agreement to support financing strategy

On December 31, 2025, Oncotelic Therapeutics, Inc. amended its independent contractor agreement with Jefferson Capital Ventures, LLC, changing the threshold for Jefferson to earn restricted stock awards from a market capitalization milestone of $100 million on a single trading day’s close to $45 million on a single trading day’s close, while leaving all other terms unchanged. The revised milestone is intended to support Oncotelic’s ongoing initiatives to activate its equity line with Mast Hills, advance future financing through AGP, and work with Sichenzia, Ross and Ferrell on a potential uplisting to a major stock exchange, signaling a strategic effort to make incentive-based equity awards more attainable and to reinforce the company’s capital markets strategy and corporate growth objectives.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Oncotelic Therapeutics completes final tranche of private financing

On December 31, 2025, Oncotelic Therapeutics, Inc. completed the third and final tranche of a private offering, issuing 44 units to 22 accredited investors under subscription agreements, while two prior investors holding a total of seven units from a 2023 private placement memorandum did not participate. Each unit in the offering consists of a $25,000 note bearing 12% annual interest maturing two years after the final closing, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, along with associated warrants to purchase additional shares of either Oncotelic or EdgePoint at preset prices, all subject to anti-dilution protections. As part of the transaction, the company treated existing 2023 notes as paid off and rolled investor contributions into the new notes, extended the life of previously issued 2023 warrants by two years, and granted investors the option to convert EdgePoint shareholdings into Oncotelic stock at an exchange rate of 10 Oncotelic shares for each EdgePoint share, potentially aligning interests more directly with the parent company; it also entered into a registration rights agreement covering the common shares issued and issuable under the financing, signaling a move to enhance liquidity and investor protections for these securities. The securities were issued under an exemption from Securities Act registration requirements, reinforcing the company’s reliance on private capital markets to support its capital structure and strategic relationship with its AI-focused subsidiary.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Oncotelic completes private convertible note and warrant financing

On December 23, 2025, Oncotelic Therapeutics, Inc. completed subscription agreements with 21 accredited investors for 32 units in a private offering of up to 500 units, each consisting of a $25,000, 12% two-year note convertible into either Oncotelic or EdgePoint AI stock, along with associated warrants in both companies subject to anti-dilution protections. The transaction, which also refinances the company’s 2023 PPM note and extends prior warrant expirations by two years while allowing investors to swap EdgePoint shares into Oncotelic stock, enhances capital flexibility and investor optionality and is supported by a registration rights agreement for underlying Oncotelic shares, potentially strengthening the company’s financing position without relying on public registration at this stage.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Oncotelic Therapeutics Launches PDAOAI Biomedical Data Platform

On December 22, 2025, Oncotelic Therapeutics, Inc. announced that it had opened access to PDAOAI, its proprietary evidence-interrogation platform built to extract biologically meaningful signals from large, complex biomedical datasets without the need to train bespoke large language models on proprietary data. The company also made available to researchers a comprehensive TGF-β literature corpus of more than 125,000 PubMed abstracts via a dedicated Discord research channel, a move that could broaden scientific engagement with its technology and strengthen its position in data-driven oncology and translational research ecosystems.

Oncotelic Therapeutics Completes Subscription Agreement with Investors

On December 4, 2025, Oncotelic Therapeutics completed a subscription agreement with accredited investors, issuing 11 units as part of a larger offering of up to 500 units. Each unit includes a note convertible into shares of Oncotelic or its subsidiary EdgePoint AI, along with warrants to purchase additional shares. This strategic financial move aims to enhance investment flexibility and extend the terms of previous warrants, potentially impacting the company’s financial structure and investor relations.

Oncotelic Therapeutics CEO Presents at LD Micro

On October 21, 2025, Oncotelic Therapeutics, Inc. announced that its CEO, Dr. Vuong Trieu, presented a corporate presentation at LD Micro in San Diego, California. The presentation included forward-looking statements about the company’s future plans, including clinical development, potential regulatory approvals, and the success of its nanoparticle platform and DAO infrastructure. These forward-looking statements highlight the company’s strategic direction and potential impacts on its operations and market positioning.